Critical Reviews™ in Therapeutic Drug Carrier Systems

ISSN for PRINT: 0743-4863

For Online Access

Best Paper Award Selection - Editorial Board Site

2003, Volume20

Issue 2&3

154 pages

DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23

Issue price - $322.00

Zhengrong Cui
Center for Pharmaceutical Science and Technology, College of Pharmacy, University of Kentucky, Lexington, KY 40536

Russell J. Mumper, Ph.D.
Assistant Director, Center for Pharmaceutical Science and Technology， College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082, USA

DNA vaccines, also referred to as genetic vaccines, are generating significant preclinical and clinical interest. It has been proven that the expression of an antigen or antigens from plasmid DNA (pDNA) may elicit both humoral and cellular immune responses. Therefore, DNA vaccines may have potential as new vaccines for important pathogens such as HIV, hepatitis C, tuberculosis, and malaria. However, the clinical results using "naked" pDNA have been disappointing in the breadth and depth of the immune response and the relatively high doses of pDNA needed to elicit a response. Clinical trials with the gene gun have been promising, but it is unclear whether this technology will be commercially viable. As a result, there exists a clear need for new vaccine delivery systems that can be administered at low doses to elicit strong humoral and cellular immune responses. One promising approach is the development of microparticles and nanoparticles as delivery systems for DNA vaccines. In this review, the application of microparticles and nanoparticles as DNA vaccine delivery systems will be critically reviewed with a primary focus on those systems that have generated in vivo immune responses.

DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10 Download article, 36 pages

Article price - $60.00

  Next article >>